Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus LEDERCILLIN VK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus LEDERCILLIN VK.
AMPICILLIN TRIHYDRATE vs LEDERCILLIN VK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
Penicillin V is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is bactericidal against susceptible organisms during the active growth phase.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
None Documented
None Documented
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
Terminal elimination half-life is 0.5 hours (range 0.4–0.6 hours) in adults with normal renal function. In severe renal impairment (CrCl <10 mL/min), half-life extends to ~4 hours.
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Renal elimination predominantly via tubular secretion of unchanged drug (>90% of absorbed dose). Approximately 20-40% of an oral dose is recovered in urine as unchanged penicillin V. Biliary excretion accounts for <1% of elimination; fecal elimination is negligible.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic